Research Projects & Grants

For Profit Organization

  • NRG-GY018, A Phase Ill Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage Ill or IVA, Stage IVB or Recurrent Endometrial Cancer (NCT # 03914612) (09/24/2019), Role: PI, Southwest Oncology Group, (02/2024) Status: Completed
  • SWOG / NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer, Role: PI, Southwest Oncology Group, (12/2019) Status: Completed
  • Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors, Role: Investigator, Southwest Oncology Group, (01/2024 - 01/2025) Status: Approved
  • SWOG -EAY131: Molecular analysis for therapy choice (MATCH), Role: Investigator, Southwest Oncology Group, (08/2019 - 08/2020) Status: Completed
  • GOG-263: Randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy, Role: PI, Southwest Oncology Group, (09/2023 - 09/2024) Status: Approved

Internal

  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2023 - 09/2024) Status: Approved
  • Investigator Initiated – Retrospective Chart Review: Referral Patterns in Gynecologic Oncology, Role: Investigator, LLU Dept. of Gynecology & Obstetrics, (11/2023) Status: Approved
  • Exploring hormone replacement therapy in those who have undergone treatment for gynecologic cancers, Role: PI, LLU Dept. of Gynecology & Obstetrics, (02/2022) Status: Approved
  • Efficacy of Ultrasound Guided Transversus Abdominis Plane (TAP) Block in Robotic Gynecological Oncology Procedures: A Retrospective Review, Role: Investigator, LLU Dept. of Anesthesiology, (12/2021) Status: Approved
  • Incidence and Outcomes of Cervical Cancer Cases at a Rural Hospital in Malawi, Role: PI, LLU Dept. of Gynecology & Obstetrics, (01/2022) Status: Approved
  • Investigator Initiated - Should Routine Appendectomy Be Performed During Open Gynecologic Oncology Surgery?, Role: Investigator, LLU Dept. of Gynecology & Obstetrics, (09/2021) Status: Approved
  • Impact of COVID-19 pandemic on cancer screening and follow up, Role: Investigator, LLU Dept. of Surgery, (12/2020) Status: Approved
  • MRI, Sonographic Findings, Delivery Outcomes, and the Risk of Accreta Development., Role: Investigator, LLU Dept. of Gynecology & Obstetrics, (02/2020) Status: Approved
  • Investigator initiated retrospective analysis of resuscitative Endovascular Balloon Occlusion (REBOA) use in placental disorder to minimize blood loss and other morbidities, Role: PI, LLU Dept. of Gynecology & Obstetrics, (09/2019) Status: Approved
  • Investigator initiated: Retrospective analysis to determine the incidence of Occult Cervical cancer in patients with Adenocarcinoma in situ at LLU, Role: PI, LLU Dept. of Gynecology & Obstetrics, (02/2019) Status: Approved
  • Investigator initiated- Retrospective chart review: Addition of spinal anesthesia to general anesthesia for reduction of postoperative pain and length of stay in open gynecologic oncology cases, Role: Investigator, LLU Dept. of Gynecology & Obstetrics, (10/2020 - 09/2021) Status: Completed
  • Investigator initiated: Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in breast and gynecologic-oncology patients: A prospective, randomized, open-label study, Role: Investigator, LLU Dept. of Gynecology & Obstetrics, (02/2024 - 02/2025) Status: Approved
  • Compassionate use of everolimus: Individual patient program (IPP) for treatment of recurrent progressive clear cell endocervical cancer with everolimus, Role: PI, LLU Dept. of Gynecology & Obstetrics, Status: Completed
  • Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy, Role: Investigator, LLU Dept. of Medicine, (04/2023 - 04/2024) Status: Completed
  • Sexual and marital dysfunction in women with gynecologic cancer, Role: PI, LLU Dept. of Gynecology & Obstetrics, (06/2015 - 06/2016) Status: Completed
  • Collection of female reproductive tissue samples, Role: Investigator, LLU Basic Science, (01/2015 - 01/2016) Status: Completed
  • GCAT 2024 - Reversing Chemoresistance in Organoid and Patient-Derived Xenograft Models of Ovarian Cancer, Role: PD/PI, LLU School of Medicine, (01/2024 - 12/2025) Status: Awarded
  • Reversing Chemoresistance in Recurrent Ovarian Cancer, Role: PD/PI, LLU School of Medicine, (01/2022 - 12/2024) Status: Awarded
  • Improving genetic testing rates to enable targeted therapy: Novel combination therapy targeting Snail and PARP for advanced ovarian cancer in Hispanic women, Role: PD/PI, LLU School of Medicine, (01/2018 - 12/2021) Status: Closed
  • Development of a metastatic ovarian cancer patient-derived xenograft model, Role: PD/PI, LLU School of Medicine, (01/2015 - 12/2016) Status: Closed

Non-Profit Organization

  • Improving genetic testing rates for ovarian cancer precision medicine: Combination therapy targeting Snail and PARP1 in ovarian cancer subtypes, Role: Co-PD/PI, Mary Kay Foundation, (07/2018 - 06/2020) Status: Closed

State

  • Targeting cancer stem cells to prevent recurrence and metastasis of ovarian cancer, Role: Co-Investigator, California Institute for Regenerative Medicine, (03/2018 - 02/2020) Status: Closed